多发性骨髓瘤移植不合格定义不一致的系统综述
该系统综述评估了截至2025年3月的II、III、IV期随机对照试验,纳入55项入组移植不合格或延迟移植的新诊断多发性骨髓瘤研究。仅47%的试验明确定义了不合格标准,其中44%使用年龄截断值,仅两项研究明确指定了具体合并症;年龄截断最常用为≥65岁,参与者中位年龄62至78.5岁呈上升趋势(p=0.1388)。
要点
- 仅47%的移植不合格试验明确定义了不合格标准。
- 年龄截断最常用为≥65岁,仅两项研究明确具体合并症。
- 仅22%的研究报告了衰弱工具,体能状态报告不一致。
核心结论
- 入组移植不合格新诊断多发性骨髓瘤的随机对照试验在定义不合格标准方面存在显著异质性。
- 缺乏基于证据的移植不合格定义,增加了研究解读和临床决策的复杂性。
研究设计与样本
- 系统综述评估截至2025年3月的II、III和IV期随机对照试验。
- 共纳入55项入组移植不合格或延迟移植的新诊断多发性骨髓瘤患者的研究。
主要发现
- 55项移植不合格试验中仅47%明确定义了不合格标准。
- 定义标准的试验中44%使用年龄截断值,伴或不伴其他标准。
- 仅两项研究明确指定了构成移植不合格的具体合并症。
- 年龄截断最常用为≥65岁。
- 试验参与者中位年龄范围为62岁至78.5岁,随时间呈上升趋势(p=0.1388)。
关键数值与推荐
- 年龄截断最常用为≥65岁。
- 22%的研究报告了衰弱工具。
- 体能状态报告不一致。
临床怎么用
- 移植不合格的判定仍应个体化。
- 缺乏统一证据定义时,需谨慎解读相关试验结果并用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM). A substantial proportion of patients are deemed ineligible for ASCT due to age, comorbidities, performance status and/or frailty. Criteria defining transplant ineligibility remain inconsistent and poorly characterized. We conducted a systematic review that assessed phase II, III and IV randomized controlled trials (RCTs) through March 2025. We included a total of 55 studies that enrolled transplant-ineligible/deferred NDMM patients. Among 55 transplant-ineligible trials, only 47% explicitly defined ineligibility criteria. Of these, 44% of trials used age as a cut-off with/without other criteria. Only two studies explicitly specified which comorbidities constituted transplant ineligibility. When age was utilized as a cut-off, age ≥65 was the most commonly used cut-off. The median age of participants in these trials ranged from 62 years to 78.5 years and showed a trend upwards over time (p = 0.1388). Performance status of enrolled patients was reported inconsistently. Frailty tools were reported in 22% of studies. RCTs enrolling transplant-ineligible patients with NDMM demonstrated considerable heterogeneity in defining ineligibility. While the decision to pursue ASCT remains individualized, the absence of evidence-based definitions of transplant ineligibility complicates research interpretation and clinical decision-making.
引用
- Neupane K, Singstock M, Shah D, et al. Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review. Br J Haematol. 2026. PMID: 41482478. doi:10.1111/bjh.70323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。